I find it interesting that nothing is noted about how the placebo group repsonded. Remember, this tells us alot about the type of patients that were included for this trial. The development of new lesions was controlled in almost 70% of these patients.
This is one of the reasons that reading only what Biogen puts out in their press releases doesn't necessarily give us the entire picture. These releases are very carefully written to maximize the positive aspect of a product....something every pharmaceutical company is good at doing.
That's why it is so important that the peer group of MS docs review the trial data when it comes out. Companies like Seron, Teva and Burlex I'm sure will have some comments to make!